Cargando…
Considering sex-specific adverse drug reactions should be a priority in pharmacovigilance and pharmacoepidemiological studies
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933181/ https://www.ncbi.nlm.nih.gov/pubmed/31891147 http://dx.doi.org/10.1016/j.eclinm.2019.11.009 |
| _version_ | 1783483154770690048 |
|---|---|
| author | Lapeyre-Mestre, Maryse |
| author_facet | Lapeyre-Mestre, Maryse |
| author_sort | Lapeyre-Mestre, Maryse |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6933181 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-69331812019-12-30 Considering sex-specific adverse drug reactions should be a priority in pharmacovigilance and pharmacoepidemiological studies Lapeyre-Mestre, Maryse EClinicalMedicine Commentary Elsevier 2019-11-23 /pmc/articles/PMC6933181/ /pubmed/31891147 http://dx.doi.org/10.1016/j.eclinm.2019.11.009 Text en © 2019 Published by Elsevier Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Commentary Lapeyre-Mestre, Maryse Considering sex-specific adverse drug reactions should be a priority in pharmacovigilance and pharmacoepidemiological studies |
| title | Considering sex-specific adverse drug reactions should be a priority in pharmacovigilance and pharmacoepidemiological studies |
| title_full | Considering sex-specific adverse drug reactions should be a priority in pharmacovigilance and pharmacoepidemiological studies |
| title_fullStr | Considering sex-specific adverse drug reactions should be a priority in pharmacovigilance and pharmacoepidemiological studies |
| title_full_unstemmed | Considering sex-specific adverse drug reactions should be a priority in pharmacovigilance and pharmacoepidemiological studies |
| title_short | Considering sex-specific adverse drug reactions should be a priority in pharmacovigilance and pharmacoepidemiological studies |
| title_sort | considering sex-specific adverse drug reactions should be a priority in pharmacovigilance and pharmacoepidemiological studies |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933181/ https://www.ncbi.nlm.nih.gov/pubmed/31891147 http://dx.doi.org/10.1016/j.eclinm.2019.11.009 |
| work_keys_str_mv | AT lapeyremestremaryse consideringsexspecificadversedrugreactionsshouldbeapriorityinpharmacovigilanceandpharmacoepidemiologicalstudies |